- Home
- MIRM vs TSI Comparison
MIRM vs TSI Comparison
Compare MIRM & TSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- TSI
- Stock Information
- Founded
- MIRM 2018
- TSI 1987
- Country
- MIRM United States
- TSI United States
- Employees
- MIRM N/A
- TSI N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- TSI Investment Managers
- Sector
- MIRM Health Care
- TSI Finance
- Exchange
- MIRM Nasdaq
- TSI Nasdaq
- Market Cap
- MIRM 1.9B
- TSI 229.4M
- IPO Year
- MIRM 2019
- TSI N/A
- Fundamental
- Price
- MIRM $42.54
- TSI $4.88
- Analyst Decision
- MIRM Strong Buy
- TSI
- Analyst Count
- MIRM 11
- TSI 0
- Target Price
- MIRM $58.55
- TSI N/A
- AVG Volume (30 Days)
- MIRM 437.9K
- TSI 106.8K
- Earning Date
- MIRM 05-12-2025
- TSI 01-01-0001
- Dividend Yield
- MIRM N/A
- TSI 7.46%
- EPS Growth
- MIRM N/A
- TSI N/A
- EPS
- MIRM N/A
- TSI N/A
- Revenue
- MIRM $336,888,000.00
- TSI N/A
- Revenue This Year
- MIRM $29.51
- TSI N/A
- Revenue Next Year
- MIRM $20.27
- TSI N/A
- P/E Ratio
- MIRM N/A
- TSI N/A
- Revenue Growth
- MIRM 80.76
- TSI N/A
- 52 Week Low
- MIRM $23.83
- TSI $4.48
- 52 Week High
- MIRM $54.23
- TSI $4.87
- Technical
- Relative Strength Index (RSI)
- MIRM 53.41
- TSI 54.86
- Support Level
- MIRM $38.22
- TSI $4.71
- Resistance Level
- MIRM $39.87
- TSI $4.84
- Average True Range (ATR)
- MIRM 1.92
- TSI 0.06
- MACD
- MIRM 0.49
- TSI 0.01
- Stochastic Oscillator
- MIRM 93.09
- TSI 85.00
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About TSI TCW Strategic Income Fund Inc.
Tcw Strategic Income Fund Inc operates as a closed-end management investment company. Its investment objective is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as airlines, banks, beverages, biotechnology, chemicals, computers, diversified financial services, entertainment and others.